Methods of treating conditions related to the s1p1 receptor
AssigneeArena Pharmaceuticals, Inc.
InventorSnehal U. Naik
Life of this patent
Estimating the term…
Abstract
Provided is a method of determining if an individual is a responder to treatment with (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid (Compound 1) or a pharmaceutically acceptable salt, solvate or hydrate thereof.
Claims59
(canceled)
(canceled)
(canceled)
A method for the treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder in an individual in need thereof, comprising the steps of:
- administering to the individual a therapeutically effective amount of Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof;
- determining whether the individual is a responder or is selected for treatment;
- and
- continuing administration of the Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual is identified as a responder, or
- modifying the administration of the Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual if the individual is not identified as a responder.
A method for the treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder in an individual in need thereof, comprising:
- administering Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual for a first time period;
- continuing administration of Compound 1 for a second time period if the individual achieves at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% reduction in fecal calprotectin by the first time period.
A method for the treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder in an individual in need thereof, comprising:
- administering Compound 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual for a first time period;
- continuing administration of Compound 1 for a second time period if the individual achieves at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95% reduction in C-reactive protein by the first time period.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.